Application No. 10/663,589
Preliminary Amendment dated 02 May 2005
Page 3 of 8

## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (previously presented) A pharmaceutical composition comprised of an aqueous solution comprising synthetic peptide in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor; wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 70 mg/ml and not more than 500 mg/ml; and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition.
- 2. (previously presented) The pharmaceutical composition according to claim 1, wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml.
- 3. (previously presented) The pharmaceutical composition according to claim 1, wherein the polyol is in a final concentration of no less than 10 weight % and no more than 50 weight % of the pharmaceutical composition.
- 4. (previously presented) The pharmaceutical composition according to claim 1, wherein the polyol comprises polyethylene glycol.
- 5. (previously presented) The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable carrier additional to the polyol.
- 6. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 1.
- 7. (previously presented) A pharmaceutical composition comprised of an aqueous solution comprising synthetic peptide in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor; wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 100 mg/ml and not

Application No. 10/663,589 Amendment dated 02 May 2005 Page 4 of 8

more than 250 mg/ml; and wherein the polyol is in a final concentration of no less than 10 weight % and no more than 50 weight % of the pharmaceutical composition.

- 8. (previously presented) The pharmaceutical composition according to claim 7, wherein the polyol comprises polyethylene glycol.
- 9. (previously presented) The pharmaceutical composition according to claim 7, further comprising a pharmaceutically acceptable carrier additional to the polyol.
- 10. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 7.
- 11. (previously presented) A synthetic peptide-containing pharmaceutical composition as a unit dose, wherein the pharmaceutical composition comprises an aqueous solution comprising: (a) a polyol present as a pharmaceutically acceptable carrier in an amount not less than 5 weight % and not more than 75 weight % of the pharmaceutical composition as a unit dose; and (b) synthetic peptide comprising an HIV fusion inhibitor in a final concentration of the pharmaceutical composition of not less than 70 mg/ml and not more than 500 mg/ml.
- 12. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 11, wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml.
- 13. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 11, wherein the polyol is in a final concentration of no less than 10 weight % and no more than 50 weight % of the pharmaceutical composition.
- 14. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 11, wherein the polyol comprises polyethylene glycol.

Application No. 10/663,589 Amendment dated 02 May 2005 Page 5 of 8

- 15. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 11, further comprising a pharmaceutically acceptable carrier additional to the polyol.
- 16. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 11.
- 17. (previously presented) A synthetic peptide-containing pharmaceutical composition as a unit dose, wherein the pharmaceutical composition comprises an aqueous solution comprising: (a) a polyol present as a pharmaceutically acceptable carrier in an amount not less than 10 weight % and not more than 50% of the pharmaceutical composition as a unit dose; and (b) synthetic peptide comprising an HIV fusion inhibitor in a final concentration of the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml.
- 18. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 17, wherein the polyol comprises polyethylene glycol.
- 19. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 17, further comprising a pharmaceutically acceptable carrier additional to the polyol.
- 20. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 17.
- 21. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 5.

Application No. 10/663,589 Amendment dated 02 May 2005 Page 6 of 8

- 22. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 9.
- 23. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 15.
- 24. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 19.
- 25. (new) The pharmaceutical composition according to claim 9, wherein the pharmaceutically acceptable carrier, additional to the polyol, comprises an aqueous alcohol.
- 26. (new) The synthetic peptide-containing pharmaceutical composition according to claim 15, wherein the pharmaceutically acceptable carrier, additional to the polyol, comprises an aqueous alcohol.
- 27. (new) The synthetic peptide-containing pharmaceutical composition according to claim 19, wherein the pharmaceutically acceptable carrier, additional to the polyol, comprises an aqueous alcohol.
- 28. (new) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 25.
- 29. (new) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 26.